📊 COLL Key Takeaways
Is Collegium Pharmaceutical, Inc. (COLL) a Good Investment?
Collegium Pharmaceutical demonstrates strong revenue growth (23.6% YoY) and robust free cash flow generation (29.4% margin), supported by solid balance sheet fundamentals (0.08x debt/equity). However, declining diluted EPS despite revenue expansion, weak capital returns (ROE 4.6%, ROA 0.9%), and concerning interest coverage (1.8x) signal operational challenges and potential capital inefficiency that warrant caution.
Collegium Pharmaceutical shows strong fundamental momentum, with revenue up 23.6% year over year, solid gross and operating margins, and exceptionally strong free cash flow conversion. The balance sheet appears manageable given ample cash, low reported long-term debt, and healthy liquidity, but flat net income and declining diluted EPS suggest growth is not fully flowing through to shareholders yet.
Collegium Pharmaceutical, Inc. Key Strengths (COLL)
- Strong topline growth of 23.6% YoY indicating market demand
- Excellent gross margins of 60.6% and solid operating margins of 16.0%
- Robust free cash flow generation of $56.8M (29.4% of revenue)
- Low financial leverage with 0.08x debt/equity ratio and $268.6M cash position
- Healthy liquidity ratios (current 1.71x, quick 1.62x)
- Strong top-line growth with 23.6% year-over-year revenue expansion
- High cash generation, with $327.58M of free cash flow and a 42.0% FCF margin
- Healthy operating profile supported by 59.3% gross margin, 23.0% operating margin, solid liquidity, and low reported leverage
COLL Stock Risks: Collegium Pharmaceutical, Inc. Investment Risks
- Diluted EPS declined 7.0% YoY despite 23.6% revenue growth, indicating operational or share dilution headwinds
- Dangerously low interest coverage ratio of 1.8x leaves minimal buffer for rate increases or covenant breaches
- Weak capital efficiency with ROE of 4.6% and ROA of 0.9% despite strong margins
- Large spread between operating income ($30.9M) and net income ($14.5M) suggests significant below-the-line expenses or tax burden
- Insider activity (9 Form 4 filings in 90 days) warrants monitoring for adverse signaling
- Net income was flat year over year and diluted EPS declined 7.0%, indicating some earnings pressure despite revenue growth
- Net margin is materially lower than operating margin, suggesting below-the-line costs or other earnings drag
- Total liabilities remain high relative to equity, which limits balance-sheet flexibility if operating conditions weaken
Key Metrics to Watch
- EPS trajectory and earnings quality to reverse recent decline
- Interest coverage ratio trend and debt refinancing activity
- Return on equity improvement and capital allocation discipline
- Operating margin sustainability amid revenue scaling
- Free cash flow conversion rate and use of proceeds
- Net income and diluted EPS conversion relative to revenue growth
- Free cash flow sustainability and margin retention
Collegium Pharmaceutical, Inc. (COLL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 29.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
COLL Profit Margin, ROE & Profitability Analysis
COLL vs Healthcare Sector: How Collegium Pharmaceutical, Inc. Compares
How Collegium Pharmaceutical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Collegium Pharmaceutical, Inc. Stock Overvalued? COLL Valuation Analysis 2026
Based on fundamental analysis, Collegium Pharmaceutical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Collegium Pharmaceutical, Inc. Balance Sheet: COLL Debt, Cash & Liquidity
COLL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Collegium Pharmaceutical, Inc.'s revenue has grown significantly by 152% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.29 reflects profitable operations.
COLL Revenue Growth, EPS Growth & YoY Performance
COLL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $177.8M | $2.4M | $0.07 |
| Q3 2025 | $159.3M | $2.4M | $0.27 |
| Q2 2025 | $145.3M | $2.4M | $0.34 |
| Q1 2025 | $144.9M | $2.4M | $0.07 |
| Q3 2024 | $136.7M | $9.3M | $0.27 |
| Q2 2024 | $135.5M | -$4.4M | $-0.13 |
| Q1 2024 | $144.8M | -$17.4M | $-0.51 |
| Q3 2023 | $127.0M | $457.0K | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Collegium Pharmaceutical, Inc. Dividends, Buybacks & Capital Allocation
COLL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Collegium Pharmaceutical, Inc. (CIK: 0001267565)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 20, 2026 | 4 | xslF345X06/form4-05202026_040501.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_040516.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_040514.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_040512.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_040517.xml | View → |
❓ Frequently Asked Questions about COLL
What is the AI rating for COLL?
Collegium Pharmaceutical, Inc. (COLL) has a Combined AI Grade of A from Claude (B) and ChatGPT (A) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COLL's key strengths?
Claude: Strong topline growth of 23.6% YoY indicating market demand. Excellent gross margins of 60.6% and solid operating margins of 16.0%. ChatGPT: Strong top-line growth with 23.6% year-over-year revenue expansion. High cash generation, with $327.58M of free cash flow and a 42.0% FCF margin.
What are the risks of investing in COLL?
Claude: Diluted EPS declined 7.0% YoY despite 23.6% revenue growth, indicating operational or share dilution headwinds. Dangerously low interest coverage ratio of 1.8x leaves minimal buffer for rate increases or covenant breaches. ChatGPT: Net income was flat year over year and diluted EPS declined 7.0%, indicating some earnings pressure despite revenue growth. Net margin is materially lower than operating margin, suggesting below-the-line costs or other earnings drag.
What is COLL's revenue and growth?
Collegium Pharmaceutical, Inc. reported revenue of $193.5M.
Does COLL pay dividends?
Collegium Pharmaceutical, Inc. does not currently pay dividends.
Where can I find COLL SEC filings?
Official SEC filings for Collegium Pharmaceutical, Inc. (CIK: 0001267565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COLL's EPS?
Collegium Pharmaceutical, Inc. has a diluted EPS of $0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is COLL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Collegium Pharmaceutical, Inc. has a A grade with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is COLL stock overvalued or undervalued?
Valuation metrics for COLL: ROE of 4.6% (sector avg: 15%), net margin of 7.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is COLL's AI grade for 2026?
Our dual AI analysis gives Collegium Pharmaceutical, Inc. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COLL's free cash flow?
Collegium Pharmaceutical, Inc.'s operating cash flow is $57.1M, with capital expenditures of $270.0K. FCF margin is 29.4%.
How does COLL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 7.5% (avg: 12%), ROE 4.6% (avg: 15%), current ratio 1.71 (avg: 2).